Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Upgraded by Zacks Investment Research to “Hold”

Zacks Investment Research upgraded shares of Armata Pharmaceuticals (NYSEAMERICAN:ARMP) from a sell rating to a hold rating in a research note published on Tuesday morning, Zacks.com reports.

According to Zacks, “Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company’s principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California. “

Separately, HC Wainwright reiterated a buy rating and set a $9.50 price objective on shares of Armata Pharmaceuticals in a research note on Wednesday, November 13th.

ARMP opened at $3.00 on Tuesday. Armata Pharmaceuticals has a 1 year low of $2.45 and a 1 year high of $6.23.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last issued its earnings results on Tuesday, November 12th. The company reported ($0.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.33).

Several large investors have recently made changes to their positions in ARMP. BlackRock Inc. purchased a new position in shares of Armata Pharmaceuticals in the second quarter worth about $45,000. Vanguard Group Inc. purchased a new position in Armata Pharmaceuticals during the second quarter valued at approximately $61,000. Finally, Stifel Financial Corp purchased a new position in Armata Pharmaceuticals during the third quarter valued at approximately $84,000.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains.

Recommended Story: FTSE 100 Index

Get a free copy of the Zacks research report on Armata Pharmaceuticals (ARMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.